Lupin’s subsidiary -- Lupin Manufacturing Solutions (LMS) has expended its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions.

With global drug development increasingly defined by molecular complexity, such as peptides and biologic ADCs, this expansion reinforces LMS’s capability to consistently supply high-quality peptide building blocks, including protected amino acids.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.